Kang Miao

Department Of Thoracic Oncology NHC Key Laboratory Of Cancer And Metabolism Clinical Oncology School Of Fujian Medical University
Fuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 14 publications

Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).

Safety and Efficacy of Aumolertinib as First-Line Treatment in EGFR-Mutant Lung Adenosquamous Carcinoma: A Multicenter, Single-Arm, Prospective Phase II Study (ARISE Study).

Journal: MedComm
Published: August 05, 2025

Early Local Treatment Delays Multiple Metastases in Non-Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study.

Early Local Treatment Delays Multiple Metastases in Non-Small Cell Lung Cancer With Solitary Distant Metastasis: A Multicenter Retrospective Cohort Study.

Journal: MedComm
Published: July 15, 2025

Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

Chinese Expert Consensus on Leptomeningeal Metastases of Lung Cancer.

Journal: Thoracic cancer
Published: April 19, 2025

Characterization of renal injury in non-squamous non-small cell lung cancer patients treated with pemetrexed: A single-center retrospective study.

Characterization of renal injury in non-squamous non-small cell lung cancer patients treated with pemetrexed: A single-center retrospective study.

Journal: Thoracic cancer
Published: June 26, 2024

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.

Savolitinib versus crizotinib for treating MET positive non-small cell lung cancer.

Journal: Thoracic cancer
Published: December 21, 2022

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non- small cell lung cancer.

Corrigendum: Peripheral blood lymphocyte subsets predict the efficacy of immune checkpoint inhibitors in non- small cell lung cancer.

Journal: Frontiers in immunology
Published: November 29, 2022

Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review.

Incidence rate and treatment strategy of immune checkpoint inhibitor mediated hepatotoxicity: A systematic review.

Journal: Cancer pathogenesis and therapy
Published: September 20, 2022

Pyrotinib-associated acute kidney injury: A case report.

Pyrotinib-associated acute kidney injury: A case report.

Journal: Cancer innovation
Published: September 02, 2022

Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects.

Pathogenesis, pathological characteristics and individualized therapy for immune-related adverse effects.

Journal: Chinese medical journal pulmonary and critical care medicine
Published: June 11, 2022

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer.

Journal: Frontiers in immunology
Published: April 04, 2022

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China.

Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China.

Journal: Frontiers in oncology
Published: January 22, 2022

Second primary tumor after immune checkpoint inhibitor therapy: A case report.

Second primary tumor after immune checkpoint inhibitor therapy: A case report.

Journal: Thoracic cancer
Published: December 06, 2021
Showing 1-12 of 14

Last Updated: 09/26/2026